company background image
34LA logo

Alpine Immune Sciences DB:34LA Stock Report

Last Price

€36.80

Market Cap

€2.4b

7D

12.9%

1Y

409.7%

Updated

24 Mar, 2024

Data

Company Financials +

Alpine Immune Sciences, Inc.

DB:34LA Stock Report

Market Cap: €2.4b

Alpine Immune Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alpine Immune Sciences
Historical stock prices
Current Share PriceUS$36.80
52 Week HighUS$38.20
52 Week LowUS$6.15
Beta1.13
1 Month Change22.67%
3 Month Change110.29%
1 Year Change409.70%
3 Year Change297.84%
5 Year Change512.31%
Change since IPO411.04%

Recent News & Updates

Recent updates

Shareholder Returns

34LADE BiotechsDE Market
7D12.9%4.5%1.4%
1Y409.7%34.1%7.5%

Return vs Industry: 34LA exceeded the German Biotechs industry which returned 34.1% over the past year.

Return vs Market: 34LA exceeded the German Market which returned 7.5% over the past year.

Price Volatility

Is 34LA's price volatile compared to industry and market?
34LA volatility
34LA Average Weekly Movement20.2%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 34LA's share price has been volatile over the past 3 months.

Volatility Over Time: 34LA's weekly volatility has increased from 13% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007142Mitch Goldhttps://www.alpineimmunesciences.com

Alpine Immune Sciences, Inc. operates as clinical-stage biopharmaceutical company. It focuses on discovery and development of immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, that is in Phase 2 clinical stage for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways, that is in preclinical trial for treatment of systemic lupus erythematosus.

Alpine Immune Sciences, Inc. Fundamentals Summary

How do Alpine Immune Sciences's earnings and revenue compare to its market cap?
34LA fundamental statistics
Market cap€2.39b
Earnings (TTM)-€29.78m
Revenue (TTM)€54.48m

43.8x

P/S Ratio

-80.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
34LA income statement (TTM)
RevenueUS$58.88m
Cost of RevenueUS$80.90m
Gross Profit-US$22.03m
Other ExpensesUS$10.16m
Earnings-US$32.18m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.49
Gross Margin-37.41%
Net Profit Margin-54.66%
Debt/Equity Ratio0%

How did 34LA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.